Influenza: A unique problem in vaccination

Future Virology

Volumn 5, Issue 5, 2010, Pages 651-664

  Johansson, Bert E ^b   Eichelberger, Maryna C ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NONE

Author keywords

hemagglutinin; influenza; M2e; neuraminidase; vaccines

Indexed keywords

HEMAGGLUTININ; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; NUCLEOPROTEIN; SIALIDASE; VIRUS ANTIGEN;

ANTIGENIC VARIATION; ANTIGENICITY; BACULOVIRUS; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; VIRUS IMMUNITY; VIRUS PARTICLE; VIRUS STRAIN; YEAST;

ORTHOMYXOVIRIDAE;

EID: 77957301930     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.46     Document Type: Review

References (119)

1. Kilbourne ED: Perspectives on pandemics: a research agenda. J. Infect. Dis. 176 (Suppl. 1), S29-S31 (1997). □ Excellent perspective on the global influenza vaccine research effort.
2. Gottschalk A: Neuraminidase: the specific enzyme of influenza virus and Vibro cholerae. Biochem. Biophys. Acta 23, 645 (1957).
3. Johansson B, Bucher D, Kilbourne E: Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J. Virol. 63, 1239 (1989).
4. Kilbourne E, Couch R, Kasel J et al.: Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 13, 1799 (1995).
5. Lamb R, Choppin P: Gene structure and replication of influenza virus. Virology 81, 382 (1983).
6. Zebedee S, Richardson C, Lamb R: Characterization of the influenza virus M2 integral membrane protein and expression at the infected-cell surface from cloned cDNA. J. Virol. 56, 502 (1985).
7. Boulo S, Akarsu H, Ruigrok RW et al.: Nuclear traffic of influenza virus proteins and ribonucleoprotein complexes. Virus Res. 124 (1-2), 12-21 (2007).
8. Wang X, Li M, Zheng H et al.: Influenza A virus NS1 protein prevents activation of NF-κB and induction of α/β interferon. J. Virol. 74(24), 11566-11573 (2000).
9. Chen W, Calvo PA, Malide D et al.: A novel influenza A virus mitochondrial protein that induces cell death. Nat. Med. 7(12), 1306-1312 (2001).
10. Johansson B, Kilbourne E: Immunization with dissociated neuraminidase, matrix, nucleoproteins from influenza A virus eliminates cognate help and antigenic competition. Virology 225, 136 (1996).
11. Murphy BR, Nelson DL, Wright PF, Tierney EL, Phelan MA, Chanock RM: Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect. Immun. 36, 1102-1108 (1982).
12. Burlington DB, Clements ML, Meiklejohn G, Phelan M, Murphy BR: Hemagglutinin specific antibody responses in immunoglobulin G, A, M isotypes as measured by enzyme-linked immunosorbent assay after primary or secondary infection of humans with influenza A virus. Infect. Immun. 41, 540-545 (1983).
13. Kilbourne ED: Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans. J. Infect. Dis. 134, 385 (1976).
14. Kendal A, Noble G, Dowdle W: Neuraminidase content of influenza vaccines and neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. J. Inf. Dis. 136, S145 (1977).
15. Tanimoto T, Nakatsu R, Fuke I et al.: Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography. Vaccine 23(37), 4598-4609 (2005).
16. McMurry JA, Johansson BE, De Groot AS: T cell directed influenza vaccines. Hum. Vaccine 4, (2008).
17. McMicheal A, Grotch F, Cullen P, Askonas B, Webster R: The human cytotoxic T cell response to influenza vaccination. Clin. Exp. Immunol. 43, 276 (1981).
18. LaMontagne JR, Noble GR, Quinnan GV et al.: Summary of clinical trials of inactivated influenza vaccine. Rev. Infect. Dis. 5, 723-736 (1983).
19. Lawson C, Bennink J, Restifo N, Yewdell J, Murphy BR: Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J. Virol. 68, 3505 (1994).
20. Doherty PC, Turner SJ, Webby RG, Thomas PG: Influenza and the challenge for immunol ogy. Nat. Immunol. 7, 449-455 (2006).
21. Ross TM, Mahmood K, Crevar CJ et al.: A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One 4(6), e6032 (2009).
22. Pushko P, Tumpey TM, Van Hoeven N et al.: Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 25(21), 4283-4290 (2007).
23. + T cells against influenza induced by vaccination with nucleoprotein DNA. J. Virol. 72, 5648-5653 (1998).
24. Montgomery DL: Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol. 12, 777-7783 (1993).
25. Donnelly JJ: Pre-clinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med. 1, 583-587 (1995).
26. Donnelly JJ: Further protection against antigenic drift of influenza virus in a ferret model with a DNA vaccine. Vaccine 15, 865-868 (1997).
27. Wise T, Polin R, Mazur M, Ennis F: Serologic responses after two sequential doses of influenza A/New Jersey/76 virus vaccine in normal young adults. J. Infect. Dis. 136, 5496 (1977).
28. McLaren C, Verbonitz MW, Daniel S, Guggs G, Ennis F: Effect of priming infection on serologic response to whole and subunit influenza virus vaccines in animals. J. Immunol. 125, 2679 (1977).
29. Gross P, Ennis F, Gaerlan L, Denson L, Denning C, Schiffman D: A controlled double-blind comparison of the reactogenicity, immunogenicity, protective efficacy of whole-virus and split-product influenza vaccines in children. J. Infect. Dis. 136, 623 (1977).
30. Scherle PA, Gerhard W: Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones in vivo. Proc. Natl Acad. Sci. USA 85, 4446-4450 (1988). □□ Experimental description of cognate help in influenza.
31. Johansson B, Moran T, Kilbourne E: Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc. Natl Acad. Sci. USA 7(84), 6869 (1987).
32. Lanzavecchia A: Antigen-specific interaction between T and B cells. Nature 314, 537 (1985).
33. Johansson B, Moran T, Bona C, Popple S, Kilbourne E: Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J. Immunol. 139, 2010 (1987).
34. Johansson BE, Moran TM, Bona CA, Kilbourne ED: Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemaggluti nin: reduced generation of neuramindase specific helper T cells in hemagglutinin primed mice. J. Immunol. 139, 2015-2019 (1987).
35. + T-cell repertoire of responses to influenza A virus hemagglutinin after recent natural infection. J. Virol. 69, 7497-7506 (1995).
36. Kilbourne ED: Influenza. Plenum Publishing, NY, USA 164-165 (1987).
37. Hobson D, Curry RL, Beare AS, Ward-Gardner A: The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond). 70(4), 767-777 (1972).
38. Eichelberger M, Golding H, Hess M et al.: FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007 Vaccine 26, 4299-4303 (2008). □ Current review of the correlates of immunity to influenza.
39. Sandbulte MR, Gao J, Straight TM, Eichelberger MC: A miniaturized assay for influenza neuraminidase inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza Other Resp. Viruses 3, 233-240 (2009).
40. Forrest BD, Pride MW, Dunning AJ et al.: Correlation of cellular immune responses with protection against culture-confrmed influenza virus in young children. Clin. Vaccine Immunol. 15(7), 1042-1053 (2008).
41. Kilbourne ED, Johansson BE, Moran TM et al.: Implications for vaccine production of influenza A virus hemagglutinin polymorphism. Pleotropic antigenic variant of A/Shangai/11/87 (H3N2) virus selected as high-yield reas sortant. J. Gen. Virol. 74, 1311-1316 (1993).
42. Both G, Sleigh M, Cox N et al.: Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. J. Virol. 48, 52-60 (1983). □□ Analysis of antigenic drift in hemagglutin in.
43. Air GM, Laver WG, Webster RG: Antigenic variation in influenza viruses. Contrib. Microbiol. Immunol. 8, 20-59 (1987).
44. Berton MT, Naeve CW, Webster RG: Antigenic structure of the influenza B virus hem agglutinin: nucleotide sequence analysis of antigenic variants selected with monoclonal antibodies. J. Virol. 52, 919-927 (1984).
45. Hensley SE, Das SR, Bailey AL et al.: Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 326(5953), 734-736 (2009).
46. Kilbourne E, Grajower B, Johansson B: Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase. Proc. Natl Acad. Sci. USA 87, 786 (1990).
47. Huddleston JA, Brownlee GG: The sequence of the nucleoprotein gene of human influenza A virus, strain A/NT/60/68. Nucleic Acids Res. 10, 1029-1038 (1982).
48. Campbell CH, Webster RG, Breese SS Jr: The in vivo production of "new" influenza A viruses. Virology 44, 317-328 (1971).
49. Kilbourne ED: Influenza Pandemics of the 20th Century. CDC Emerging Infectious Diseases, GA, USA (2006).
50. Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG: Characterization of the 1918 influenza virus polymerase genes. Nature 437, 889-893 (2005). □ Describes an alternative mechanism of emerging influenza strains.
51. Shope RE: The influenza viruses of swine and man. Harvey Lect. 30, 183-213 (1936).
52. Chun JWH: Influenza, including its infection among pigs. Natl Med. J. China 5, 34-44 (1919).
53. Reid A, Taubenberger HJK: The origin of the 1918 pandemic influenza virus: a continuing enigma. J. Gen. Virol. 84, 2285-2292 (2003).
54. Pappas CPV, Aguilar CF, Basler A et al.: Single gene reassortants identify a critical role for PBl, HA, NA in the high virulence of the 1918 pandemic influenza virus. Proc. Natl Acad. Sci. USA 105, 3064-3069 (2008).
55. Belshe RB: A review of attenuation of influenza viruses by genetic manipulation. Am. J. Respir. Crit. Care Med. 152, S72-S75 (1995).
56. Johansson BE, Kilbourne ED: Influenza vaccine strain selection: equivalence of two antigenically distinct hemagglutinin variants of 1989 H3N2 influenza virus in protection of mice. Vaccine 10(9), 603-606 (1992).
57. Smith DJ, Lapedes AS, de Jong JC et al.: Mapping the antigenic and genetic evolution of influenza virus. Science 305, 371-376 (2004).
58. Wise T, Polin R, Mazur M, Ennis F: Serologic responses after two sequential doses of influenza A/New Jersey/76 virus vaccine in normal young adults. J. Infect. Dis. 136, 5496 (1977).
59. Treanor JJ, Campbell, JD, Zangwill KM, Rowe T, Wolff M: Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343-1351 (2006).
60. American Academy of Pediatrics. Vaccination against influenza. In: The Red Book: Report of the Committee on Infectious Diseases. Elk Grove Village, IL, USA (2007).
61. Johansson BE, Kilbourne ED: Comparative long term effects in a mouse model system of influenza whole virus vaccine and purifed neuraminidase vaccine followed by sequential infections. J. Infect. Dis. 162, 800-809 (1990).
62. Besselaar TG, Botha L, McAnerney JM, Schoub BD: Antigenic and molecular analysis of influenza A (H3N2) virus strains isolated from a localised influenza outbreak in South Africa in 2003. J. Med. Virol. 73, 71-78 (2004).
63. Brett IC, Johansson BE: Immunization against influenza A virus: comparison of conventional inactivated, live attenuated and recombinant baculovirus produced purifed hemagglutinin and neuraminidase vaccines in a murine model system. Virology 339(2), 273-280 (2005). □ Proof of principle of neuraminidasesupplemented vaccines.
64. Belshe R, Gruber W, Mendelman P et al.: Efficacy of vaccina tion with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatrics 136, 168-175 (2000).
65. Karron RA, Talaat K, Luke C et al.: Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 27(36), 4953-4960 (2009).
66. Belshe RB, Edwards KM, Vesikari T et al.; EM CAIV-T Comparative Efficacy Study Group: Live attenuated versus inacti vated influenza vaccine in infants and young children. N Engl. J. Med. 356, 685-696 (2007).
67. Ashkenazi S, Vertruyen A, Arístegui J et al.: CAIV-T Study Group Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr. Infect. Dis. J. 10, 870-879 (2006).
68. Demicheli V, Rivetti D, Deeks J, Jefferson T: Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev. CD001269 (2008).
69. Smith S, Demicheli V, Di Pietrantonj C et al.: Vaccines for preventing influenza in healthy children. Cochrane Database Syst. Rev. CD004879 (2007).
70. Rivetti D, Jefferson T, Thomas R et al.: Vaccines for preventing influenza in the elderly. Cochrane Database Syst. Rev. 3, CD004876 (2007).
71. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V: Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 366(9492), 1165-1174 (2005). □ Excellent review of the effectiveness of influenza vaccines. (Pubitemid 41393594)
72. Johansson BE: Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 17, 10, 2073-2080 (1999).
73. Johansson BE, Pokorny BA, Tiso VA: Supplementation of conventional trivalent influenza vaccine with purifed viral N1 and N2 neuraminidase induces a balanced immune response without antigenic competition. Vaccine 20, 1670-1674 (2002).
74. Couch R, Kasel J, Gerin J, Schulman J, Kilbourne E: Induction of partial immunity to influenza by a neuraminidase-specific influenza A virus vaccine in humans. J. Infect. Dis. 129, 411 (1974).
75. Couch R, Douglas R, Fedson D, Kasel J: Correlated studies of a recombinant influenza virus vaccine. III. Protection against experimental influenza in man. J. Infect. Dis. 124, 473 (1971).
76. Kilbourne E, Couch R, Kasel J et al.: Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 13, 1799 (1995).
77. Martinet W: Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase. Eur. J. Biochem. 247(1), 332-338 (1997).
78. Chen Z, Matsuo K, Asanuma H et al.: Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin-and neuraminidase-expressing DNAs. Vaccine 17, 653-659 (1999).
79. Schiff G, Kilbourne E, Smith G, Hackett C, Manoff S, Matthews J: Phase 2 clinical evaluation of an influenza A virus recombinant N2 neuraminidase vaccine. Presented at: The First European Influenza Congress. Hersonessos, Crete, Greece, 23-28 September 2000.
80. Sandbulte MR: Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 4(2), e59 (2006).
81. + T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain. Vaccine 26, 52, 6965-6974 (2008).
82. Lee Y, Sung H, Choi J et al.: Effects of homologous and heterologous neuraminidase vaccines in chickens against H5N1 highly pathogenic avian influenza. Avian Dis. 51 (Suppl. 1), 476-478 (2005).
83. Hinshaw R, Webster G, Turner B: Novel influenza A viruses isolated from canadian feral ducks: including strains antigenically related to swine influenza (HSW1N1) viruses. J. Gen. Virol. 41, 115-127 (1978).
84. Sylte MJ, Suarez DL: Influenza neuraminidase as a vaccine antigen. In: Vaccines for Pandemic Influenza. Compans R, Orenstein W (Eds). Curr. Top. Microbiol. Immunol. 333, 227-241 (2009).
85. Liu W, Li H, Chen Y-H: N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol. Med. Microbiol. 35, 141-146 (2003).
86. Black RA, Rota PA, Gorodkova N, Klenk HD, Kendal AP: Antibody response to M2 protein of influenza A virus expressed in insect cells. J. Gen. Virol. 74, 143-146 (1993).
87. Mozdzanowska K, Feng J, Eid M et al.: Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21, 2616-2626 (2003).
88. de Filette M, Min Jou W, Birkett A et al.: Universal influenza A vaccine: optimization of M2-based constructs. Virology 337, 149-161 (2005). □ Proof of principle of M2e immunization.
89. Frace AM, Klimov AI, Rowe T, Black RA, Katz JM: Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 17, 2237-2244 (1999).
90. Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi ATJ: Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J. Gen. Virol. 83, 1851-1859 (2002).
91. Lakey A: Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J. Infect. Dis. 174(4), 838-841 (1996).
92. Treanor JJ: Dose-related safety and immunogenicity of a trivalent baculovirusexpressed influenza-virus. J. Infect. Dis. 193, 1223 (2006).
93. Treanor JJ, Schiff GM, Hayden FG et al.: Safety and immunogenicity of a baculovirusexpressed hemagglutinin influenza vaccine: a randomized controlled trial. J. Am. Med. Assoc. 297(14), 1577-1582 (2007).
94. Treanor J: Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19, 1732-1737 (2001).
95. Ross TM, Mahmood K, Crevar CJ et al.: A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One 4(6), e6032 (2009).
96. Pushko P, Tumpey TM, Van Hoeven N et al.: Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza Vaccine 25, 21, 4283-4290 (2007).
97. Johansson B, Brett I: Variation in cation requirements of influenza A N2 neuraminidases. J. Biochem. 134, 345-352 (2003).
98. Brett IC, Johansson BE: Variation in cation requirements of influenza A N1 neuraminidases. J. Biochem. 139, 3, 439-447 (2006).
99. Lu X, Humeau L, Slepushkin V et al.: Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J. Gen. Med. 6, 963-973 (2004).
100. Saelens X, Vanlandschoot P, Martinet W et al.: Protection of mice against a lethal influenza virus challenge after immunization with yeast-derived secreted influenza virus hemagglutinin. Eur. J. Biochem. 260, 166-175 (1999).
101. Yongkiettrakul S, Boonyapakron K, Jongkaewwattana A et al.: Avian influenza A/H5N1 neuraminidase expressed in yeast with a functional head domain. J. Virol. Methods 156 (1-2), 44-51 (2009).
102. Jansen KU, Rosolowsky M, Schultz LD et al.: Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation Vaccine 13(16), 1509-1514 (1995).
103. Encke J, Putlitz J, Wands JR: DNA Vaccines. Intervirology 1999(42), 117-124 (1999). □ Concise review of DNA vaccines.
104. Chen Z, Hagiwara S, Yoshikawa T et al.: Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 18(28), 3214-3222 (2000).
105. Ulmer JB, Donnelly JJ, Parker SE et al.: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259(5102), 1745-1749 (1993).
106. Okuda K, Ihata A, Watabe S et al.: Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 19, 27, 3681-3691 (2001).
107. Ulmer JB: Heterologous protection against influenza by injection of DNA encoding a viral protein Science 259, 1745-1749 (1993).
108. Deck RR: Characterization of humoral immune responses induced by an influenza haemagglutinin DNA vaccine. Vaccine 15, 71-78 (1997).
109. Robinson HL, Hunt LA, Webster RG: Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 11, 957-960 (1993).
110. Donnelly JJ: Further protection against antigenic drift of influenza virus in a ferret model with a DNA vaccine. Vaccine 15, 865-868 (1997).
111. Donnelly JJ: Pre-clinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med. 1, 583-587 (1995).
112. Johansson BE, Matthews JT, Kilbourne ED: Supplementation of conventional influenza A vaccine with purifed viral neuraminidase results in a balanced and broadened immune response. Vaccine 16, 9, 1009-1015 (1998).
113. Liu MA: Gene-based vaccines: recent developments. Curr. Opin. Mol. Ther. 12(1), 86-93 (2010).
114. Wesley RD, Tang M, Lager KM: Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus. Vaccine 22 (25-26), 3427-3434 (2004).
115. Gao W, Soloff AC, Lu X et al.: Protective vaccine for the rapid response to lethal avian influenza outbreaks. J. Virol. 80, 1959-1964 (2006).
116. Hoelscher MA, Singh N, Garg S et al.: A broadly-protective pandemic influenza vaccine against clade 1 and clade 2 H5N1 viruses. J. Infect. Dis. 197(8), 1185-1188 (2008).
117. Price GE, Soboleski MR, Lo CY, et al, Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27(47), 6512-6521 (2009).
118. Prausnitz MR, Mikszta JA, Cormier M, Rianov AK: Microneedle-based vaccines. Curr. Top. Microbiol. Immunol. 333, 369-393 (2009).
119. Martínez-Sobrido L, Cadagan R, Steel J et al.: Hemagglutinin-pseudotyped green fuorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies. J. Virol. 84(4), 2157-2163 (2010).